Ochsner Health and Paradigm Health expand access to clinical trials across the Gulf South
Paradigm Health's AI-driven recruitment platform reviews and identifies potential trial patients across 47 Ochsner hospitals and 370 health centers, expanding Ochsner patients' access to trials by 41%. Clinical trials can offer patients important treatment options and renewed hope. With multiple trial sites throughout Louisiana, Ochsner…
Clinical trials can offer patients important treatment options and renewed hope. With multiple trial sites throughout Louisiana, Ochsner had a strong foundation to expand participation across its network and connect more patients to research opportunities closer to home.
To support that growth, Paradigm Health introduced an efficient way to assess patient eligibility across a large population by assisting research staff in the review process. Ochsner implemented Paradigm Health's AI-powered patient recruitment platform, which integrates within electronic health records and other clinical data.
What Happened
This enabled research teams to reassess eligibility in near real time without additional administrative burden. The LLM-native eligibility assessment allowed clinical staff to review eligibility of the most likely candidates only and spend more time directly engaging and supporting patients with trial.
Paradigm Health's AI-driven recruitment platform reviews and identifies potential trial patients across 47 Ochsner hospitals and 370 health centers, expanding Ochsner patients' access to trials by 41%.
Nationally recognized for its commitment to clinical excellence and digital innovation, Ochsner served 1.6 million individuals from across the globe in 2025, supported by a dedicated team of 40,000 employees and 5,000 physicians.
In April 2026, Paradigm Health announced a landmark research collaboration with the FDA focused on advancing a new model to accelerate clinical trial execution and regulatory review.
Key Details
"By pinpointing eligible patients sooner in their treatment path and tracking changing eligibility status, we are making our clinical trial infrastructure more efficient and expanding the reach of Ochsner's research team to consider and enroll more patients in need of trials as.
The model uses Paradigm Health's technology-enabled Study Conduct platform to allow real-time review by the FDA, by automating data collection and analysis, and streamlining the reporting of key safety and efficacy signals to trial.
For more information about how Paradigm Health is expanding clinical trial access in rural America, visit www.paradigmhealth.ai or read the comprehensive case study at https://www.paradigmhealth.ai/ochsner-case-study.
Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm Health aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations.
Why It Matters
The Gulf South's premier nonprofit academic healthcare system, Ochsner Health, provides specialized medical services via a network of 47 hospitals and over 370 clinics and urgent care facilities.
Paradigm Health has engineered an AI-powered platform to make clinical trials more accessible and efficient, so that patients, researchers, and study sponsors can maximize the impact of clinical research.
For additional details on Ochsner's mission to improve community health, visit www.ochsner.org.
What Reports Say
Coverage of the story so far points to:
Continued reporting by Yahoo Finance as more details emerge
